Trade IDEAYA Biosciences, Inc. - IDYA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 38.56 |
| Open | 38.02 |
| 1-Year Change | 104.85% |
| Day's Range | 38.02 - 40.21 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2024 | 38.56 | -0.20 | -0.52% | 38.76 | 39.83 | 37.76 |
| Apr 24, 2024 | 39.81 | 1.05 | 2.71% | 38.76 | 40.20 | 38.76 |
| Apr 23, 2024 | 38.97 | 1.40 | 3.73% | 37.57 | 39.44 | 37.52 |
| Apr 22, 2024 | 37.51 | 0.37 | 1.00% | 37.14 | 38.40 | 36.54 |
| Apr 19, 2024 | 37.05 | -0.16 | -0.43% | 37.21 | 38.24 | 36.54 |
| Apr 18, 2024 | 37.55 | -2.05 | -5.18% | 39.60 | 39.80 | 37.47 |
| Apr 17, 2024 | 40.09 | -1.10 | -2.67% | 41.19 | 41.30 | 39.63 |
| Apr 16, 2024 | 41.06 | -0.58 | -1.39% | 41.64 | 41.91 | 40.56 |
| Apr 15, 2024 | 41.43 | -0.43 | -1.03% | 41.86 | 42.55 | 40.88 |
| Apr 12, 2024 | 41.87 | -0.22 | -0.52% | 42.09 | 43.60 | 41.19 |
| Apr 11, 2024 | 43.36 | 2.60 | 6.38% | 40.76 | 43.54 | 40.76 |
| Apr 10, 2024 | 42.21 | 0.94 | 2.28% | 41.27 | 42.34 | 41.03 |
| Apr 9, 2024 | 42.52 | 1.47 | 3.58% | 41.05 | 42.58 | 41.04 |
| Apr 8, 2024 | 41.93 | -0.53 | -1.25% | 42.46 | 42.60 | 41.36 |
| Apr 5, 2024 | 42.45 | 1.28 | 3.11% | 41.17 | 42.57 | 40.35 |
| Apr 4, 2024 | 41.30 | -0.82 | -1.95% | 42.12 | 42.75 | 41.13 |
| Apr 3, 2024 | 42.06 | 1.40 | 3.44% | 40.66 | 42.10 | 40.59 |
| Apr 2, 2024 | 41.42 | -0.53 | -1.26% | 41.95 | 42.60 | 40.95 |
| Apr 1, 2024 | 42.41 | -0.57 | -1.33% | 42.98 | 44.11 | 42.29 |
| Mar 28, 2024 | 43.80 | 0.51 | 1.18% | 43.29 | 44.11 | 42.74 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
IDEAYA Biosciences, Inc. Company profile
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc. is a synthetic lethality-focused precision medicine company. The Company focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The Company’s product candidate is IDE196, a protein kinase C (PKC), inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes multiple synthetic lethality programs, including against methionine adenosyltransferase 2a (MAT2A) in tumor cells having methylthioadenosine phosphorylase (MTAP) gene deletion; Pol-theta, in tumors with genetic mutations in homologous recombination deficiency (HRD), including breast carcinoma (BRCA ) mutations; poly adenosine diphosphate-ribose glycohydrolase (PARG), in tumors with genetic mutations in BRCA or base excision repair, and Werner Helicase, in high microsatellite instability tumors (MSI) tumors.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Ideaya Biosciences Inc revenues increased 43% to $27.9M. Net loss increased 44% to $49.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balanci increase of 42% to $54.7M (expense), Stock-based Compensation in SGA increase from $1.2M to $4.7M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
7000 Shoreline Ct Ste 350
SOUTH SAN FRANCISCO
CALIFORNIA 94080-7604
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com